Applying the German Version of the TOMMORROW Neuropsychological Assessment Battery for the diagnosis of Mild Cognitive Impairment in Clinical and Research Settings

Among cognitively healthy participants, the TOMMORROW study (NCT01931566) aimed to identify those who went on to develop MCI due to AD over time (see Burns et al., 2021). Thus, based on the criteria of DSM‐5 and Albert et al. (2011) a battery of neuropsychological tests, i.e., TOMMORROW Neuropsychological Assessment battery (TOMM‐NAB) was compiled to assess cognition: memory (California Verbal Learning Test (CVLT‐II) long‐delay free recall, CVLT‐II short‐delay free recall, Brief Visuospatial Memory Test–Revised (BVMT‐R) delayed recall); executive function (Trail Making Test (TMT) B, digit span backward); language (semantic fluency (animals), lexical fluency (S‐, D, F‐words), Multilingual Naming Test (MiNT)); attention (TMT A, digit span forward) and visuospatial function (Clock Drawing Test (CDT), BVMT‐R copy). For the study subjects at the German‐speaking TOMMORROW study site, normative data were collected from 198 cognitively healthy individuals (see Romero et al., 2018). The goal of this study was to make the normative data of this excellent NAB available to clinicians and researchers in German‐speaking Europe.